This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.
Participant has provided informed consent prior to initiation of any study specific activities/procedures.
Age greater than or equal to 18 years old at the same time of signing the informed consent.
Histologically or cytologically confirmed for Solid Tumor.
Eastern Cooperative Oncology Group (ECOG) 0 to 1.
History of other malignancy within the past 5 years with exceptions.
Systemic chemotherapy was administered within 3 weeks prior to the first administration.
Activated symptomatic brain metastases and leptomeningeal disease.
History of inflammatory bowel disease.